Javitt Jonathan C 4
4 · NRX Pharmaceuticals, Inc. · Filed Sep 10, 2025
Insider Transaction Report
Form 4
Javitt Jonathan C
DirectorChairman and Chief Scientist10% Owner
Transactions
- Award
Stock Option (right to buy)
2025-04-09+125,000→ 125,000 totalExercise: $1.73Exp: 2035-04-09→ Common Stock (125,000 underlying)
Footnotes (1)
- [F1]Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. 1/3 of the Options shall vest on the first anniversary of the grant date, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to continued